SAN DIEGO – Pharmacyclics Inc. grabbed the spotlight on Friday with a $150 million up-front deal that could reach a total of $975 million with Janssen Biotech Inc. for Phase II hematologic cancer drug PCI-32765. At the 53rd Annual American Society of Hematology meeting, hematologists and investors got to see some of what all the fuss is about.